Skip to main content
SpringerLink
Log in

Predictive tests in cancer chemotherapy a reappraisal

  • Übersichten
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

The evolution of medical oncology so far owes much to the preclinical and clinical development of antineoplastic agents. Prognostic factors and empiric treatment strategies have guided the clinician in his choice of drugs. In the light of increasing ethical restrictions met with phase I–II clinical trials and major advances in propagating human tumor cells outside the donor patient, a reappraisal of predictive tests in cancer chemotherapy is warranted. Among ‘short-term assays’ only the determination of steroid-hormone receptor content in tumor tissues has gained clinical acceptance, whereas other methods still suffer from theoretical or practical shortcomings.

Both the human tumor stem cell assay and the xenograft model have revealed unique patterns of sensitivity for each individual tumor line. While interindividual heterogeneity among tumors sharing a common site of origin justifies efforts to develop predictive tests, microheterogeneity among tumor samples from the same donor patient limits the potential of this approach.

Predictive tests should be performed in conjunction with clinical trials to ensure optimal extraction of information. As additional prognostic factors, they should in the near future accelerate drug development and reduce the hazard of unnecessary drug toxicity without therapeutic benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Asano S, Mandel TE (1981) Colonies formed in agar from human breast cancer and their identification as T-lymphocytes. JNCI 67:25–32

    CAS  PubMed  Google Scholar 

  2. Bagshawe KD (1980) Marker proteins as indicators of tumour response to therapy. Br J Cancer [Suppl IV] 41:186–190

    Google Scholar 

  3. Bastert G, Schmidt-Matthiesen H, Michel RT, Fortmeyer HP, Sturm R, Nord D, Gerner R (1977) Human mammary cancers in nu/nu mice. Model for testing in research and clinic. Klin Wochenschr 55:83–84

    Article  CAS  PubMed  Google Scholar 

  4. Becher R, Osieka R, Hossfeld DK, Schmidt CG (1981) Cytogenetic studies in human tumour xenografts. In: Bastert GB, Fortmeyer HP, Schmidt-Matthiesen H (eds) Thymusaplastic nude mice and rats in clinical oncology. G. Fischer, Stuttgart New York, pp 329–334

    Google Scholar 

  5. Bedford P, Fox BW (1982) Repair of DNA interstrand crosslinks after busulphan; a possible mode of resistance. Cancer Chemother Pharmacol 8:3–7

    Article  CAS  PubMed  Google Scholar 

  6. Begleiter A, Lam HYP, Grover J, Froese E, Goldenberg GJ (1979) Evidence for active transport of melphalan by two amino acid carriers in L5178Y lymphoblasts in vitro. Cancer Res 39:353–359

    CAS  PubMed  Google Scholar 

  7. Bertino JR (1981) Clinical use of methotrexate; with emphasis on use of high doses. Cancer Treat Rep [Suppl 1] 65:131–135

    PubMed  Google Scholar 

  8. Bhuyan BK, Scheidt LG, Fraser TJ (1972) Cell cycle phase specificity of antitumor agents. Cancer Res 32:398–407

    CAS  PubMed  Google Scholar 

  9. Bogden AE, Kelton DE, Cobb WR, Esber HJ (1978) A rapid screening method for testing chemotherapeutic agents against human tumor xenografts. In: Houchens DP, Ovejera AA (eds) Proceedings of the Symposium on the Use of Athymic (Nude) Mice in Cancer Research, Columbus, Ohio, June 15–16, 1977. G. Fischer, Stuttgart, pp 231–250

    Google Scholar 

  10. Braunschweiger PG, Poulakos L, Schiffer LM (1976) In vitro labeling and gold activation autoradiography for determination of labeling index and DNA synthesis times of solid tumors. Cancer Res 36:1748–1753

    CAS  PubMed  Google Scholar 

  11. Burns CP, Armentrout SA, Stjernholm RL (1972) Prediction of the response of patients with acute nonlymphocytic leukemia to cytosine arabinoside (NSC-63878) therapy. Cancer Chemother Rep 56:527–534

    CAS  PubMed  Google Scholar 

  12. Carter SK (1978) Cancer chemotherapy as it approaches middle age. Cancer Chemother Pharmacol 1:1–4

    CAS  PubMed  Google Scholar 

  13. Carter SK (1981) Predictors of response and their clinical evaluation. Cancer Chemother Pharmacol 7:1–4

    Article  CAS  PubMed  Google Scholar 

  14. Chen HSG, Gross JF (1980) Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 64:31–40

    CAS  PubMed  Google Scholar 

  15. Day RS III, Ziolkowski CHJ, Scudiero DA, Meyer SA, Lubiniecki AS, Girardi AJ, Galloway SM, Bynum GD (1980) Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature 288:724–727

    Article  CAS  PubMed  Google Scholar 

  16. Deisseroth A, Abrams RA (1979) The role of autologous stem cell reconstitution in intensive therapy for resistant neoplasms. Cancer Treat Rep 63:461–471

    CAS  PubMed  Google Scholar 

  17. DeVita VT Jr, Young RC, Canellos GP (1975) Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35:98–110

    Article  PubMed  Google Scholar 

  18. DeVita VT Jr (1978) The evolution of therapeutic research in cancer. N Engl J Med 298:907–910

    Article  PubMed  Google Scholar 

  19. DeVita VT Jr (1983) The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 51:1209–1220

    Article  PubMed  Google Scholar 

  20. Dertinger H, Huelser D (1981) Increased radioresistance of cells in cultured multicell spheroids. I. Dependence on cellular interaction. Radiat Environ Biophys 19:101–107

    Article  CAS  PubMed  Google Scholar 

  21. Ducore JM, Erickson LC, Zwelling LA, Laurent G, Kohn KW (1982) Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum(II) andL-phenylalanine mustard. Cancer Res 42:897–902

    CAS  PubMed  Google Scholar 

  22. Durand RE, Olive PL (1981) Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res 41:3489–3494

    CAS  PubMed  Google Scholar 

  23. Epstein J, Preisler H (1981) Effects of cytosine arabinoside on DNA synthesis as predictor for acute myelocytic leukemia (AML) patients' response to chemotherapy. Eur J Cancer 17:623–628

    Article  CAS  PubMed  Google Scholar 

  24. Erickson LC, Zwelling LA, Ducore JM, Sharkey NA, Kohn KW (1981) Differential cytotoxicity and DNA cross-linking in normal and transformed human fibroblasts treated with cis-diamminedichloroplatinum(II). Cancer Res 41:2791–2794

    CAS  PubMed  Google Scholar 

  25. Ewig RAG, Kohn KW (1977) DNA damage and repair in mouse leukemia L1210 cells treated with nitrogen mustard, 1,3-bis(2-chloroethyl)-1-nitrosourea, and other nitrosoureas. Cancer Res 37:2114–2122

    CAS  PubMed  Google Scholar 

  26. Farrands PA, Perkins AC, Pimm MV, Hardy JD, Embleton MJ, Baldwin RW, Hardcastle JD (1982) Radioimmunodetection of human colorectal cancers by an antitumour monoclonal antibody. Lancet 2:397–400

    Article  CAS  PubMed  Google Scholar 

  27. Fisher RI, DeVita VT Jr, Hubbard SM, Longo DL, Wesley R, Chabner BA, Young RC (1983) Diffuse aggressive lymphomas: Increased survival after flexible sequences of Pro-MACE and MOPP chemotherapy. Ann Intern Med 98:304–309

    Article  CAS  PubMed  Google Scholar 

  28. Frei E III (1982) The National Cancer Chemotherapy Program. Science 217:600–606

    Article  PubMed  Google Scholar 

  29. Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439–449

    CAS  PubMed  Google Scholar 

  30. Hakala MT, Rustum YM (1979) The potential value of in vitro screening. In: DeVita VT Jr, Busch H (eds) Methods in cancer research, vol 16: Cancer drug development, part A. Academic Press, New York San Francisco London, pp 247–287

    Google Scholar 

  31. Hamburger AW (1981) Use of in vitro tests in predictive cancer chemotherapy. JNCI 66:981–988

    CAS  PubMed  Google Scholar 

  32. Hamburger AW, White CP, Brown RW (1981) Effect of epidermal growth factor on proliferation of human tumor cells in soft agar. JNCI 67:825–830

    CAS  PubMed  Google Scholar 

  33. Hamburger AW, White CP, Tencer K (1982) Effect of enzymatic disaggregation on proliferation of human tumor cells in soft agar. Proc Am Assoc Cancer Res 23:182 [Abstr 716]

    Google Scholar 

  34. Hiddemann W, Buechner T, Andreeff M, Woermann B, Melamed MR, Clarkson BD (1982) Cell kinetics in acute leukemia. A critical reevaluation based on new data. Cancer 50:250–258

    Article  CAS  PubMed  Google Scholar 

  35. Hill BT (1978) The management of human “solid” tumours: some observations on the irrelevance of traditional cell cycle kinetics and the value of certain recent concepts. Cell Biol Int Rep 2:215–230

    Article  Google Scholar 

  36. Hill BT, Whelan RDH, Rupniak HT, Dennis LY, Rosholt MA (1981) A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Pharmacol 7:21–26

    Article  CAS  PubMed  Google Scholar 

  37. Houghton JA, Taylor DM (1978) Maintenance of biological and biochemical characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br J Cancer 37:199–212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Houghton JA, Maroda SJ Jr, Phillips JO, Houghton PJ (1981) biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 41:144–149

    CAS  PubMed  Google Scholar 

  39. Houghton PJ, Houghton JA, Taylor DM (1977) Effects of cytotoxic agents on TdR incorporation and growth delay in human colonic tumour xenografts. Br J Cancer 36:206–214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Houghton PJ, Houghton JA (1978) Evaluation of single-agent therapy in human colorectal tumour xenografts. Br J Cancer 37:833–840

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. KSST (Group of Sensitivity Testing of Tumors): In vitro short-term tests to determine the resistance of human tumors to chemotherapy. Cancer 48:2127–2135

  42. Laskin JD, Evans RM, Slocum HK, Burke D, Hakala MT (1979) Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res 39:383–390

    CAS  PubMed  Google Scholar 

  43. Lenhard RE, Woo KB, Abeloff MD (1983) Predictive value of regression rates following chemotherapy of small cell carcinoma of the lung. Cancer Res 43:3013–3017

    PubMed  Google Scholar 

  44. Osborne CK, Von Hoff DD, Clark GM, Sandbach J O'Brien M (1982) The clonogenic assay identifies antagonism in combination chemotherapy of breast cancer. Proc Am Assoc Cancer Res 23:185 [Abstr 729]

    Google Scholar 

  45. Osieka R, Houchens DP, Goldin A, Johnson RK (1977) Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer 40:2640–2650

    Article  CAS  PubMed  Google Scholar 

  46. Osieka R, Schmidt CG (1982) Primary and acquired resistance to alkylating agents in heterotransplants of human melanomas and colon carcinomas. In: Reed ND (ed) Proceedings of the Third International Workshop on Nude Mice, Bozeman, MO, Sept 6–9, 1979. G. Fischer, Stuttgart New York, pp 675–684

    Google Scholar 

  47. Ovejera AA, Houchens DP (1981) Human tumor xenografts in athymic nude mice as a preclinical screen for anticancer agents. Semin Oncol 8:386–393

    CAS  PubMed  Google Scholar 

  48. Possinger K, Ehrhart H (1983) Prädiktive Tumorteste im chemotherapeutischen Behandlungskonzept maligner Erkrankungen Klin Wochenschr 61:77–84

  49. Povlsen CO, Jacobsen GK (1975) Chemotherapy of a human malignant melanoma transplanted in the nude mouse. Cancer Res 35:2790–2796

    CAS  PubMed  Google Scholar 

  50. Preisler HD (1978) Alteration of binding of the supravital dye Hoechst 33342 to human leukemic cells by adriamycin. Cancer Treat Rep 62:1393–1396

    CAS  PubMed  Google Scholar 

  51. Puck TT, Marcus PI (1955) A rapid method for viable cell titration and clone production with HeLa cells in tissue culture: the use of X-irradiated cells to supply conditioning factors. Proc Natl Acad Sci USA 41:432–437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Quayle JB (1982) Ability of CEA blood levels to reflect tumour burden: a study in a human xenograft model. Br J Cancer 46:220–227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Rajewsky MF, Mueller R, Adamkiewicz J, Drosdziok W (1980) Immunological detection and quantification of DNA components structurally modified by alkylating carcinogens (ethylnitrosourea). In: Pullman B, Ts'o POP, Gelboin H (eds): Carcinogenesis: fundamental mechanisms and environmental effects. Proceedings of the 13th jerusalem Symposium on Quantum Chemistry and Biochemistry, Jerusalem, Israel. April 28–May 2, 1980, Reidel, Dordrecht Boston London, pp 207–218

    Google Scholar 

  54. Reich SD, Pechet L, Griffin TW, Antonelli DM, Bogden AE (1982) 6-Day subrenal capsule assay: results and response to chemotherapy of patients with lymphoma. Proc Am Assoc Cancer Res 23:17 [Abstr C-68]

    Google Scholar 

  55. Roper PR, Drewinko B (1976) Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 36:2182–2188

    CAS  PubMed  Google Scholar 

  56. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230

    Article  CAS  PubMed  Google Scholar 

  57. Roos E, Dingemans KP (1979) Mechanisms of metastasis. Biochim Biophys Acta 560:135–165

    CAS  PubMed  Google Scholar 

  58. Rosman M, Lee MH, Creasey WA, Sartorelli AC (1974) Mechanisms of resistance to 6-thiopurines in human leukemia. Cancer Res 34:1952–1956

    CAS  PubMed  Google Scholar 

  59. Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1327

    Article  CAS  PubMed  Google Scholar 

  60. Salmon SE, Liu RM, Casazza AM (1981) Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6:103–110

    Article  CAS  PubMed  Google Scholar 

  61. Sanfilippo O, Daidone MG, Costa A, Canetta R, Silvestrini R (1981) Estimation of differential in vitro sensitivity of non-Hodgkin lymphomas to anticancer drugs. Eur J Cancer 17:217–226

    Article  CAS  PubMed  Google Scholar 

  62. Schabel FM Jr (1969) The use of tumor growth kinetics in planning “curative” chemotherapy of advanced solid tumors. Cancer Res 29:2384–2389

    PubMed  Google Scholar 

  63. Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR Jr, Mayo JG, Lloyd HH (1979) Testing therapeutic hypotheses in mice and man: observations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated or potential clinical utility for treatment of advanced solid tumors of man. In: DeVita VT Jr, Busch H (eds) Methods in cancer research, vol 17: Cancer drug development, part B. Academic Press, New York San Francisco London, pp 3–51

    Google Scholar 

  64. Schiffer LM, Markoe AM, Nelson JSR (1976) Estimation of tumor growth fraction in murine tumors by the primer-available DNA-dependent DNA polymerase assay. Cancer Res 36:2415–2418

    CAS  PubMed  Google Scholar 

  65. Schimke RT, Kaufman RJ, Alt FW, Kellems RF (1978) Gene amplification and drug resistance in cultured murine cells. Science 202:1051–1055

    Article  CAS  PubMed  Google Scholar 

  66. Seeber S, Schmidt CG (1977) Zum Problem der prätherapeutischen Sensibilitätsbestimmung von Tumoren durch Inkorporationsstudien in vitro. Klin Wochenschr 55:1127–1136

    Article  CAS  PubMed  Google Scholar 

  67. Selby P, Buick RN, Tannock I (1983) A critical appraisal of the ‘human tumor stem-cell assay’. N Engl J Med 308:129–134

    Article  CAS  PubMed  Google Scholar 

  68. Skipper HE, Hutchison DJ, Schabel FM, Schmidt LH, Goldin A, Brockman RW, Venditti JM, Wodinsky I (1972) A quick reference chart on cross resistance between anticancer agents. Cancer Chemother Rep 56:493–498

    CAS  PubMed  Google Scholar 

  69. Smith IE, Courtenay VD, Gordon MY (1976) A colony-forming assay for human tumour xenografts using agar in diffusion chambers. Br J Cancer 34:476–483

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Steel GG, Courtenay VD, Peckham MJ (1983) The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer 47:1–13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Swartzendruber DE (1977) A bromodeoxyuridine (BUdR)-mithramycin technique for detecting cycling and non-cycling cells by flow microfluorometry. Exp Cell Res 109:439–443

    Article  CAS  PubMed  Google Scholar 

  72. Taetle R, Koessler AK, Howel SB (1981) In vitro growth and drug sensitivity of tumor colony-forming units from human tumor xenografts. Cancer Res 41:1856–1860

    CAS  PubMed  Google Scholar 

  73. Thomas CB, Osieka R, Kohn KW (1978) DNA cross-linking by in vivo treatment with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of sensitive and resistant human colon carcinoma xenografts in nude mice. Cancer Res 38:2448–2454

    CAS  PubMed  Google Scholar 

  74. Tilley WD, Keightley DD, Cant ELM (1978) Inter-site variation of oestrogen receptors in human breast cancers. Br J Cancer 38:544–546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Tritton TR, Yee G (1982) The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 217:248–250

    Article  CAS  Google Scholar 

  76. Tutton PJM, Barkla DH (1982) Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal carcinomas. Br J Cancer 46:260–265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Twentyman PR (1980) Experimental chemotherapy studies: intercomparison of assays. Br J Cancer [Suppl IV] 41:279–287

    Google Scholar 

  78. Venditti JM (1981) Preclinical drug development: rationale and methods. Semin Oncol 8:349–361

    CAS  PubMed  Google Scholar 

  79. Vistica DT (1980) Cytotoxicity as an indicator for transport mechanism: evidence that murine bone marrow progenitor cells lack a high-affinity leucine carrier that transports melphalan in murine L1210 leukemia cells. Blood 56:427–429

    CAS  PubMed  Google Scholar 

  80. Volm M, Wayss K, Mattern J, Kleckow M, Vogt-Moykopf I (1978) Resistenztestung und Chemotherapieergebnis bei Bronchialtumoren. Dtsch Med Wochenschr 103:1266–1270

    Article  CAS  PubMed  Google Scholar 

  81. Volm M, Wayss K, Kaufmann M, Mattern J (1979) Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer 15:983–993

    Article  CAS  PubMed  Google Scholar 

  82. Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R (1981) Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 70:1027–1032

    Article  Google Scholar 

  83. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF (1983) Prospective clinical trial of a human tumor cloning system. Cancer Res 43:1926–1931

    Google Scholar 

  84. Warenius HM, Bleehen NM (1982) In vivo-in vitro clonogenic assays in a human tumour xenograft with a high plating efficiency. Br J Cancer 46:45–50

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Wick MM (1982) Therapeutic effect of dopamine infusion on human malignant melanoma. Cancer Treat Rep 66:1657–1659

    CAS  PubMed  Google Scholar 

  86. Wist E, Millar JL, Shorthouse AJ (1981) Melphalan uptake in relation to vascular and extracellular space of human lung-tumour xenografts. Br J Cancer 43:458–463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Westdeutsches Tumorzentrum Essen, Innere Universitätsklinik und Poliklinik, Germany

    R. Osieka, S. Seeber & C. G. Schmidt

Authors
  1. R. Osieka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Seeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. G. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by SFB 102 of the Deutsche Forschungsgemeinschaft (DFG)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osieka, R., Seeber, S. & Schmidt, C.G. Predictive tests in cancer chemotherapy a reappraisal. Klin Wochenschr 62, 203–212 (1984). https://doi.org/10.1007/BF01721045

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01721045

Key words

Search

Navigation